Loading organizations...
§ Private Profile · Dogokdong, South Korea
AI platform for in silico drug discovery and protein design, enabling de novo design of novel proteins and antibodies for rare diseases.
Galux, based in Seoul, South Korea, develops an AI-driven platform called GaluxDesign that integrates physics, chemistry, and artificial intelligence for in silico drug discovery and protein design. The platform enables de novo design of novel proteins and antibodies, including protein structure prediction and interaction modeling, to create therapeutics for rare diseases and incurable conditions. Operating in the biotechnology and pharmaceutical sectors, Galux is a Series B stage venture that has raised a total of $7.27 million in funding and holds 3 patents. The company reached 48 employees in February 2026 and is led by CEO Seok Cha-ok and Head Director Byungho Bae. Galux was founded in September 2020 by a team from Seoul National University with expertise in protein structure prediction.
Galux has raised $2.9B across 1 funding round.
Galux focuses on discovering and developing novel drugs specifically for incurable and rare diseases, addressing areas with significant unmet medical needs.
The GaluxDesign platform is capable of performing protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction to advance drug development.
Galux focuses on discovering and developing novel drugs specifically for incurable and rare diseases, addressing areas with significant unmet medical needs.
The GaluxDesign platform is capable of performing protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction to advance drug development.
Galux has raised $2.9B across 1 funding round. Most recently, it raised $2.9B Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2026 | $2.9B Series B | — | 유안타인베스트먼트, Daily Partners, Intervest, Korea Development Bank, Korea Investment & Securities, Mirae Asset Securities, NCORE Ventures, Pathway Capital Management, SL Investment, Sneakpeek Investments | Announced |
The GaluxDesign platform is designed to perform critical functions in molecular design. Its capabilities include protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction. These functionalities are integral to understanding and manipulating biological molecules at a fundamental level, which is crucial for creating effective new treatments.
Galux directs its efforts towards the discovery and development of novel drugs for specific therapeutic areas. The company places a particular emphasis on addressing incurable and rare diseases, aiming to provide solutions where current treatments may be limited or non-existent. This focus underscores a commitment to tackling significant unmet medical needs.
Through its innovative AI-based drug design and optimization platform, Galux seeks to accelerate the process of bringing new therapeutic options to patients. The integration of cutting-edge AI with biophysical understanding positions Galux as a contributor to the evolution of protein therapeutics.